Host |
Mouse + Rabbit |
Klon |
L26 + polyclonal |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG2a & Rabbit Ig |
Lokalisation |
Cytoplasmic, Cell Membrane, Nuclear |
pan B-Cocktail (CD20 & PAX-5)
|
Zytomed Systems GmbH |
L26 + polyclonal |
6 ml |
Ready-to-use |
RUO |
COG002 |
-
|
Host |
Mouse |
Klon |
4A4 + XM26 + LL002 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Skin, Colon Carcinoma |
Verdünnung |
- |
Isotyp |
Mouse IgG2a, IgG1, IgG3 |
Lokalisation |
Cytoplasm, nucleus |
pan Basalcell-Cocktail (p63 & Cytokeratin 5/14)
|
Zytomed Systems GmbH |
4A4 + XM26 + LL002 |
16 ml |
Ready-to-use |
RUO |
BMS051 |
-
|
Host |
Mouse |
Klon |
4A4+XM26+LL002 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Skin, Colon Carcinoma |
Verdünnung |
1:50 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cytoplasm, nucleus |
pan Basalcell-Cocktail (p63 & Cytokeratin 5/14)
|
Zytomed Systems GmbH |
4A4+XM26+LL002 |
1 ml |
Concentrate |
RUO |
CO005K |
-
|
Host |
Mouse |
Klon |
4A4+XM26+LL002 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Skin, Colon Carcinoma |
Verdünnung |
1:50 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cytoplasm, nucleus |
pan Basalcell-Cocktail (p63 & Cytokeratin 5/14)
|
Zytomed Systems GmbH |
4A4+XM26+LL002 |
0.5 ml |
Concentrate |
RUO |
CO005K-05 |
-
|
Host |
Mouse |
Klon |
4A4+XM26+LL002 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Skin, Colon Carcinoma |
Verdünnung |
- |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cytoplasm, nucleus |
pan Basalcell-Cocktail (p63 & Cytokeratin 5/14)
|
Zytomed Systems GmbH |
4A4+XM26+LL002 |
6 ml |
Ready-to-use |
RUO |
COG005 |
-
|
Host |
Mouse |
Klon |
PD7/26/16+2B11+L26+PS1+DF-T1 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil or B-cell lmyphoma or T-cell lymphoma |
Verdünnung |
- |
Isotyp |
Mouse IgG1 and Mouse IgG2 |
Lokalisation |
Cell Surface |
pan Lymphoma Cocktail
|
Biocare Medical |
PD7/26/16+2B11+L26+PS1+DF-T1 |
6 ml |
Ready-to-use |
CE/IVD |
API3035AA |
-
|
Host |
Mouse+Rabbit |
Klon |
M2-7C10+M2-9E3+T311+SP6 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Melanoma |
Verdünnung |
- |
Isotyp |
MouseIgG2a+IgG2b/kappa+rabbit IgG |
Lokalisation |
Nuclear, cytoplasmic |
Pan Melanoma + Ki-67
|
Biocare Medical |
M2-7C10+M2-9E3+T311+SP6 |
6 ml |
Ready-to-use |
CE/IVD |
PM362DSAA |
-
|
Host |
Mouse+Rabbit |
Klon |
M2-7C10+M2-9E3+T311+SP6 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Melanoma |
Verdünnung |
- |
Isotyp |
MouseIgG2a+IgG2b/kappa+IgG2b/kappa+rabbit IgG |
Lokalisation |
Nuclear, cytoplasmic |
Pan Melanoma + Ki-67
|
Biocare Medical |
M2-7C10+M2-9E3+T311+SP6 |
25 ml |
Ready-to-use |
CE/IVD |
PM362DSH |
-
|
Host |
Mouse |
Klon |
M2-7C10+M2-9E3+T311 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Diva modified Citrate pH 6.2 or pH 6.0 |
Positivkontrolle |
Melanoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG2b+IgG2b+IgG2a |
Lokalisation |
Cytoplasmic |
Pan Melanoma Cocktail-2
|
Biocare Medical |
M2-7C10+M2-9E3+T311 |
0.1 ml |
Concentrate |
CE/IVD |
CM178A |
-
|
Host |
Mouse |
Klon |
M2-7C10+M2-9E3+T311 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Diva modified Citrate pH 6.2 or pH 6.0 |
Positivkontrolle |
Melanoma |
Verdünnung |
- |
Isotyp |
Mouse IgG2b+IgG2b+IgG2a |
Lokalisation |
Cytoplasmic |
Pan Melanoma Cocktail-2
|
Biocare Medical |
M2-7C10+M2-9E3+T311 |
6 ml |
Ready-to-use |
CE/IVD |
PM178AA |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Cerebral Cortex |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Peptide human TrkA, aa777-796 |
Lokalisation |
Cytoplasm, Cell membrane, Endosomes |
Pan Trk
|
Diagnostic Biosystems |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PDR176 |
-
|
Host |
Rabbit |
Klon |
EPR17341 |
Format |
Concentrate |
Reaktivität |
CH |
Methode |
P, WB, IF |
Vorbehandlung |
EDTA |
Positivkontrolle |
Astrocytoma, Cerebral Cortex |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide within Human Pan Trk aa 800 to the C-terminus |
Lokalisation |
Cytoplasm, Cell membrane, Endosomes |
pan Trk
|
Zytomed Systems GmbH |
EPR17341 |
0.1 ml |
Concentrate |
RUO |
RBK069-01 |
-
|
Host |
Rabbit |
Klon |
EPR17341 |
Format |
Concentrate |
Reaktivität |
CH |
Methode |
P, WB, IF |
Vorbehandlung |
EDTA |
Positivkontrolle |
Astrocytoma, Cerebral Cortex |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide within Human Pan Trk aa 800 to the C-terminus |
Lokalisation |
Cytoplasm, Cell membrane, Endosomes |
pan Trk
|
Zytomed Systems GmbH |
EPR17341 |
0.5 ml |
Concentrate |
RUO |
RBK069-05 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Cerebral Cortex |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG |
Verdünnung |
Peptide human TrkA, aa777-796 |
Lokalisation |
Cytoplasm, Cell membrane, Endosomes |
Pan Trk
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP176 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Cerebral Cortex |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG |
Verdünnung |
Peptide human TrkA, aa777-796 |
Lokalisation |
Cytoplasm, Cell membrane, Endosomes |
Pan Trk
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP176-01 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Cerebral Cortex |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG |
Verdünnung |
Peptide human TrkA, aa777-796 |
Lokalisation |
Cytoplasm, Cell membrane, Endosomes |
Pan Trk
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP176-05 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Pancreas |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Pancreatic Polypeptide
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP030 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Pancreas |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Pancreatic Polypeptide
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP030-01 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Pancreas |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Pancreatic Polypeptide
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP030-05 |
-
|
Host |
Rabbit |
Klon |
SP151 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Parathyroid glands |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from the internal region of human PTH protein |
Lokalisation |
Cytoplasm |
Parathyroid Hormone (PTH)
|
Zytomed Systems GmbH |
SP151 |
1 ml |
Concentrate |
RUO |
516-4514 |
-
|
Host |
Mouse |
Klon |
BGN/1F8 |
Format |
Purified |
Methode |
F, P, EL |
Isotyp |
Mouse IgG1 |
Verdünnung |
Synthetic peptide corresponding to amino acids 1-34 of mature PTH conjugated to a proprietary carrier molecule |
Parathyroid Hormone (PTH)
|
Zytomed Systems GmbH |
BGN/1F8 |
200 µg |
Purified |
RUO |
616-0067 |
-
|
Host |
Mouse |
Klon |
ZM207 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Parathyroid. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
A synthetic peptide around aa 1-34 of human mature-PTH-polypeptide; A recombinant fragment around aa 32-115 of human mature PTH-polypeptide (exact sequence is proprietary) |
Lokalisation |
Cytoplasm |
Parathyroid hormone (PTH)
|
Zeta Corporation |
ZM207 |
1.0 ml |
Concentrate |
CE/IVD |
Z2378ML |
-
|
Host |
Mouse |
Klon |
ZM207 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Parathyroid. |
Verdünnung |
- |
Isotyp |
IgG2b /κ |
Verdünnung |
A synthetic peptide around aa 1-34 of human mature-PTH-polypeptide; A recombinant fragment around aa 32-115 of human mature PTH-polypeptide (exact sequence is proprietary) |
Lokalisation |
Cytoplasm |
Parathyroid hormone (PTH)
|
Zeta Corporation |
ZM207 |
7 ml |
Ready-to-use |
CE/IVD |
Z2378MP |
-
|
Host |
Mouse |
Klon |
ZM207 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Parathyroid. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
A synthetic peptide around aa 1-34 of human mature-PTH-polypeptide; A recombinant fragment around aa 32-115 of human mature PTH-polypeptide (exact sequence is proprietary) |
Lokalisation |
Cytoplasm |
Parathyroid hormone (PTH)
|
Zeta Corporation |
ZM207 |
0.5 ml |
Concentrate |
CE/IVD |
Z2378MS |
-
|
Host |
Mouse |
Klon |
ZM207 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Parathyroid. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
A synthetic peptide around aa 1-34 of human mature-PTH-polypeptide; A recombinant fragment around aa 32-115 of human mature PTH-polypeptide (exact sequence is proprietary) |
Lokalisation |
Cytoplasm |
Parathyroid hormone (PTH)
|
Zeta Corporation |
ZM207 |
0.1 ml |
Concentrate |
CE/IVD |
Z2378MT |
-
|
Host |
Rabbit |
Klon |
ZR224 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Renal cell carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa 223-354) of human PAX2 protein |
Lokalisation |
nucleus |
PAX-2
|
Zeta Corporation |
ZR224 |
1 ml |
Concentrate |
CE/IVD |
Z2741RL |
-
|
Host |
Rabbit |
Klon |
ZR224 |
Format |
ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Renal cell carcinoma |
Verdünnung |
--- |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa 223-354) of human PAX2 protein |
Lokalisation |
nucleus |
PAX-2
|
Zeta Corporation |
ZR224 |
7 ml |
ready-to-use |
CE/IVD |
Z2741RP |
-
|
Host |
Rabbit |
Klon |
ZR224 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Renal cell carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa 223-354) of human PAX2 protein |
Lokalisation |
nucleus |
PAX-2
|
Zeta Corporation |
ZR224 |
0.5 ml |
Concentrate |
CE/IVD |
Z2741RS |
-
|
Host |
Rabbit |
Klon |
ZR224 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Renal cell carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa 223-354) of human PAX2 protein |
Lokalisation |
nucleus |
PAX-2
|
Zeta Corporation |
ZR224 |
0.1 ml |
Concentrate |
CE/IVD |
Z2741RT |
-
|
Host |
Rabbit |
Klon |
SP34 |
Format |
Concentrate |
Reaktivität |
CK, DG, MS |
Methode |
P, FL |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide from C-terminus of human PAX-5 protein |
Lokalisation |
Nucleus |
PAX-5
|
Zytomed Systems GmbH |
SP34 |
0.1 ml |
Concentrate |
RUO |
530-3340 |
-
|
Host |
Rabbit |
Klon |
SP34 |
Format |
Concentrate |
Reaktivität |
CK, DG, MS |
Methode |
P, FL |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide from C-terminus of human PAX-5 protein |
Lokalisation |
Nucleus |
PAX-5
|
Zytomed Systems GmbH |
SP34 |
0.5 ml |
Concentrate |
RUO |
530-3342 |
-
|
Host |
Rabbit |
Klon |
SP34 |
Format |
Concentrate |
Reaktivität |
CK, DG, MS |
Methode |
P, FL |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide from C-terminus of human PAX-5 protein |
Lokalisation |
Nucleus |
PAX-5
|
Zytomed Systems GmbH |
SP34 |
1 ml |
Concentrate |
RUO |
530-3344 |
-
|
Host |
Monospecific Mouse |
Klon |
ZM26 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human full-length PAX-5 protein |
Lokalisation |
Nucleus |
PAX-5
|
Zeta Corporation |
ZM26 |
1 ml |
Concentrate |
CE/IVD |
Z2354ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM26 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human full-length PAX-5 protein |
Lokalisation |
Nucleus |
PAX-5
|
Zeta Corporation |
ZM26 |
7 ml |
Ready-to-use |
CE/IVD |
Z2354MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM26 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human full-length PAX-5 protein |
Lokalisation |
Nucleus |
PAX-5
|
Zeta Corporation |
ZM26 |
0.5 ml |
Concentrate |
CE/IVD |
Z2354MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM26 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human full-length PAX-5 protein |
Lokalisation |
Nucleus |
PAX-5
|
Zeta Corporation |
ZM26 |
0.1 ml |
Concentrate |
CE/IVD |
Z2354MT |
-
|
Host |
Rabbit |
Klon |
ZR268 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa 235-382) of human PAX-5 protein |
Lokalisation |
Nucleus |
PAX-5
|
Zeta Corporation |
ZR268 |
1 ml |
Concentrate |
CE/IVD |
Z2582RL |
-
|
Host |
Rabbit |
Klon |
ZR268 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa 235-382) of human PAX-5 protein |
Lokalisation |
Nucleus |
PAX-5
|
Zeta Corporation |
ZR268 |
7 ml |
Ready-to-use |
CE/IVD |
Z2582RP |
-
|
Host |
Rabbit |
Klon |
ZR268 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa 235-382) of human PAX-5 protein |
Lokalisation |
Nucleus |
PAX-5
|
Zeta Corporation |
ZR268 |
0.5 ml |
Concentrate |
CE/IVD |
Z2582RS |
-
|
Host |
Rabbit |
Klon |
ZR268 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa 235-382) of human PAX-5 protein |
Lokalisation |
Nucleus |
PAX-5
|
Zeta Corporation |
ZR268 |
0.1 ml |
Concentrate |
CE/IVD |
Z2582RT |
-
|
Host |
Mouse |
Klon |
BC12 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Kidney, renal cell carcinoma |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Verdünnung |
ag0306 |
Lokalisation |
Nucleus |
PAX-8
|
Diagnostic Biosystems |
BC12 |
6 ml |
Ready-to-use |
CE/IVD |
PDM180 |
-
|
Host |
Rabbit |
Klon |
ZR1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Ovarian serous carcinoma. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to the C-terminus of Human PAX8 protein |
Lokalisation |
Nucleus |
PAX-8
|
Zeta Corporation |
ZR1 |
1.0 ml |
Concentrate |
CE/IVD |
Z2202RL |
-
|
Host |
Rabbit |
Klon |
ZR1 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Ovarian serous carcinoma. |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to the C-terminus of Human PAX8 protein |
Lokalisation |
Nucleus |
PAX-8
|
Zeta Corporation |
ZR1 |
7 ml |
Ready-to-use |
CE/IVD |
Z2202RP |
-
|
Host |
Rabbit |
Klon |
ZR1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Ovarian serous carcinoma. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to the C-terminus of Human PAX8 protein |
Lokalisation |
Nucleus |
PAX-8
|
Zeta Corporation |
ZR1 |
0.5 ml |
Concentrate |
CE/IVD |
Z2202RS |
-
|
Host |
Rabbit |
Klon |
ZR1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Ovarian serous carcinoma. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to the C-terminus of Human PAX8 protein |
Lokalisation |
Nucleus |
PAX-8
|
Zeta Corporation |
ZR1 |
0.1 ml |
Concentrate |
CE/IVD |
Z2202RT |
-
|
Host |
Monospecific Mouse |
Klon |
ZM28 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Ovarian serous carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human PAX-8 protein |
Lokalisation |
Nucleus |
PAX-8
|
Zeta Corporation |
ZM28 |
1 ml |
Concentrate |
CE/IVD |
Z2357ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM28 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Ovarian serous carcinoma. |
Verdünnung |
- |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human PAX-8 protein |
Lokalisation |
Nucleus |
PAX-8
|
Zeta Corporation |
ZM28 |
7 ml |
Ready-to-use |
CE/IVD |
Z2357MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM28 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Ovarian serous carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human PAX-8 protein |
Lokalisation |
Nucleus |
PAX-8
|
Zeta Corporation |
ZM28 |
0.5 ml |
Concentrate |
CE/IVD |
Z2357MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM28 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Ovarian serous carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human PAX-8 protein |
Lokalisation |
Nucleus |
PAX-8
|
Zeta Corporation |
ZM28 |
0.1 ml |
Concentrate |
CE/IVD |
Z2357MT |
-
|
Host |
Mouse |
Klon |
PC10 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
CC1 |
Positivkontrolle |
Breast cancer or prostate cancer |
Verdünnung |
- |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant rat PCNA protein |
Lokalisation |
Nucleus |
PCNA (PC10)
|
Biocare Medical |
PC10 |
6 ml |
Ready-to-use |
CE/IVD |
AVI3255G |
-
|